Literature DB >> 1913660

Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.

R J Cote1, S C Jhanwar, S Novick, A Pellicer.   

Abstract

A putative tumor suppressor gene, p53, has been shown to be altered in a variety of human tumor types. The primary mechanism of p53 inactivation is believed to be mutation of one allele followed by loss of the second allele. Malignant mesothelioma is a tumor that has been highly associated with exposure to asbestos fibers, which are known to cause chromosomal abnormalities in mesothelial cells. We have examined four mesothelioma cell lines for genetic abnormalities in p53. Cytogenetic analysis revealed that two of the four tumors had abnormalities (numerical and/or structural) of chromosome 17 (the locus of the p53 gene). Restriction fragment length polymorphism analysis using a chromosome 17p-specific probe (pYNZ22) revealed that two tumors had loss of heterozygosity in the region of 17p13. The relative level of p53 mRNA expression was examined by Northern analysis, with one tumor showing negligible expression of p53 mRNA. The complementary DNA of p53 was generated from the three tumors showing detectable mRNA expression, and the region between codons 70 and 319 was amplified by the polymerase chain reaction and sequenced. DNA single-base substitutions were detected in two of the tumor cell lines, each resulting in amino acid substitutions. One tumor had an arginine to histidine substitution at position 175, and one tumor had a glycine to aspartic acid substitution at position 245. The observed mutations took place in regions of high cross-species sequence homology, indicating that these regions may be functionally important. The correlation of chromosomal loss in 17p on the cytogenetic and molecular level along with p53 mRNA expression and DNA sequence data indicate that genetic alterations in p53 could be a feature of malignant mesotheliomas and may reveal an important role of asbestos fibers in tumor suppressor gene inactivation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913660

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

Review 2.  Asbestos and mesothelioma: genetic lessons from a tragedy.

Authors:  A Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

3.  Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma.

Authors:  K Segers; H Backhovens; S K Singh; J De Voecht; M Ramael; C Van Broeckhoven; E Van Marck
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Mechanisms of asbestos carcinogenesis and toxicity: the amphibole hypothesis revisited.

Authors:  B T Mossman
Journal:  Br J Ind Med       Date:  1993-08

Review 5.  Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis.

Authors:  J F Lechner; J Tesfaigzi; B I Gerwin
Journal:  Environ Health Perspect       Date:  1997-09       Impact factor: 9.031

6.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

7.  Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.

Authors:  Eleonora Sementino; Craig W Menges; Yuwaraj Kadariya; Suraj Peri; Jinfei Xu; Zemin Liu; Richard G Wilkes; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  J Cell Physiol       Date:  2018-06-15       Impact factor: 6.384

8.  Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.

Authors:  Ryota Hama; Yoshiyuki Watanabe; Kanako Shinada; Yosuke Yamada; Yuka Ogata; Yoshihito Yoshida; Tomohiro Tamura; Tetsuya Hiraishi; Ritsuko Oikawa; Jo Sakurai; Tadateru Maehata; Hirotaka Koizumi; Fumio Itoh
Journal:  Tumour Biol       Date:  2012-07-27

Review 9.  Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review.

Authors:  S K Mohanty; P Dey
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

10.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

Authors:  D Esrig; C H Spruck; P W Nichols; B Chaiwun; K Steven; S Groshen; S C Chen; D G Skinner; P A Jones; R J Cote
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.